858 Therapeutics
Jim Veal has an extensive work experience in the pharmaceutical industry. Jim began their career in 1992 as a Research Investigator at GlaxoSmithKline. In 2003, they moved to Serenex as a Sr. Director of Structural Chemistry and Informatics. Jim then joined Pamlico Pharmaceutical Inc. in 2009 as Vice President of Research. In 2012, they became a Distinguished Research Fellow at Quanticel Pharmaceuticals and in 2015, they were promoted to Executive Director at Celgene Quanticel Research. Finally, in 2016, they were appointed Chief Scientific Officer at Jecure Therapeutics and in 2019, they assumed the same role at 858 Therapeutics.
Jim Veal obtained their Bachelor of Arts degree in Chemistry from Duke University between 1980 and 1983. Jim then went on to pursue a Ph.D. in Biophysics at The Florida State University, which they completed in 1989.